Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000311276 | SCV000343082 | benign | not specified | 2016-07-08 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001697651 | SCV000532144 | likely benign | not provided | 2020-12-08 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000311276 | SCV000615540 | likely benign | not specified | 2016-12-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000557316 | SCV000649015 | benign | Autosomal recessive ataxia, Beauce type; Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2024-01-13 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001156801 | SCV001318327 | likely benign | Autosomal recessive ataxia, Beauce type | 2018-01-12 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. |
Illumina Laboratory Services, |
RCV001156802 | SCV001318328 | benign | Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2018-01-12 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. |
Ambry Genetics | RCV002518058 | SCV003543781 | uncertain significance | Inborn genetic diseases | 2021-08-13 | criteria provided, single submitter | clinical testing | The c.11496G>A (p.M3832I) alteration is located in exon 70 (coding exon 69) of the SYNE1 gene. This alteration results from a G to A substitution at nucleotide position 11496, causing the methionine (M) at amino acid position 3832 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV001697651 | SCV005227905 | likely benign | not provided | criteria provided, single submitter | not provided |